ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sarepta Therapeutics, the firm that sells the muscular dystrophy drug eteplirsen, is solidifying its role in the gene-therapy field by acquiring the small start-up Myonexus Therapeutics for $165 million. Myonexus, a spin-off from Nationwide Children’s Hospital in Columbus, Ohio, is developing gene therapies to treat five forms of a rare condition called limb-girdle muscular dystrophy. Sarepta licensed these therapies from Myonexus last May.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter